On Thursday, Following Stocks were among the “Top 100 Losers” of U.S. Stock Market: Kite Pharma, Inc. (NASDAQ:KITE), Emerald Oil, Inc. (NYSEMKT:EOX), Alcatel-Lucent (NYSE:ALU), Molycorp, Inc. (NYSE:MCP)
Kite Pharma, Inc. (NASDAQ:KITE), with shares declined -7.26%, closed at $57.75.
Emerald Oil, Inc. (NYSEMKT:EOX), with shares dropped -3.19%, settled at $0.862.
Alcatel-Lucent (NYSE:ALU), with shares dipped -3.12%, and closed at $3.73.
Molycorp, Inc. (NYSE:MCP), plummeted -7.04%, and closed at $0.350.
Latest NEWS regarding these Stocks are depicted underneath:
Kite Pharma, Inc. (NASDAQ:KITE)
Kite Pharma, Inc. (KITE), stated full-year and fourth quarter 2014 financial results for the period ended December 31, 2014.
In the first half of 2015, Kite plans to initiate its first pivotal study of its lead product candidate, KTE-C19, under its IND in refractory diffuse large B cell lymphoma (DLBCL).
Corporate and Clinical Developments of 2014 and Early 2015;
The recent attainment of Netherlands-based TCF(TM), which was renamed Kite Pharma EU, establishes a European presence for Kite operations. The transaction allows Kite to expand its product pipeline of TCRs for the treatment of solid tumors, complementing its CAR pipeline. Highlights of the attainment comprise:
TCF’s proprietary, TCR-GENErator(TM) discovery platform recently developed by Professors Dr. Dirk Busch, M.D., of the Technische Universitat Munchen (TUM), a pioneer in engineering T cells, and Dr. Ton N.M. Schumacher, Ph.D., of the Netherlands Cancer Institute (NKI), a leading expert in T cell biology and gene therapy. TCR-GENErator(TM) is an industry-leading R&D engine for rapid, high-throughput identification of TCR-based product candidates, which could enter the clinic as early as 2017.
The appointment of Professor Dr. Schumacher to Chief Scientific Officer of Kite Pharma EU. Professor Dr. Schumacher will also maintain his current position as Deputy Director of the NKI, an internationally renowned research institution with clinical expertise and manufacturing capabilities. Kite’s relationship with the NKI provides an important operational platform and access to investigators, clinical sites and manufacturing facilities in Europe.
Rights to new intellectual property in the TCR space developed by Professor Dr. Schumacher at the NKI, as part of the NKI contract. In addition, Kite Pharma EU has license contracts with IBA GmbH, Sanquin Blood Supply Foundation, and the NKI that form the basis of Kite Pharma EU’s proprietary TCR-GENErator(TM) technology platform.
This attainment is the latest of several noteworthy transactions that Kite has undertaken, which comprise the following:
A major partnership with Amgen to develop and commercialize a next generation of novel CAR T cell immunotherapies. Amgen is contributing cancer targets, and Kite is leveraging its proprietary CAR platform, R&D and manufacturing capabilities and expertise. Under the contract, Kite will conduct all preclinical research and cell manufacturing and processing through IND filing, following which each corporation will be responsible for clinical development and commercialization of their respective CAR therapeutic candidates. Kite received a $60 million upfront payment from Amgen in the first quarter of 2015.
An exclusive, worldwide license with the National Institutes of Health (NIH) to certain intellectual property related to TCR-based product candidates that target the human papillomavirus (HPV) antigens E6 and E7 of the HPV subtype 16 for the treatment of cancers associated with HPV infection. This license is in addition to the May 2014 NIH license to certain intellectual property related to TCR-based product candidates targeting the NY-ESO-1 antigen found on various cancers.
An expanded CRADA with the NCI to encompass exciting, emerging areas of research, counting the next generation of TCR-based product candidates that are engineered to recognize neo-antigens, which are specific to the unique genetic profile of a patient’s own tumor.
Securing facilities, through lease contracts, to provide clinical and commercial product to support clinical development and the launch of KTE-C19.
Kite Pharma, Inc. operates a clinical-stage biopharmaceutical corporation which focuses on the development and commercialization of novel cancer immunotherapy products. The corporation is developing a pipeline of eACT-based product candidates for the treatment of solid and hematological malignancies.
Emerald Oil, Inc. (NYSEMKT:EOX)
Formerly on March 10, Emerald Oil, Inc. (EOX), declared financial and operational results for the quarter and year ended December 31, 2014.
Highlights:
- Raised fourth quarter production to 377,250 BOE, an average of about 4,101 BOEPD, an raise of 7% contrast to the third quarter of 2014 and 71% contrast to the fourth quarter of 2013;
- Raised annual production to 1,295,230 BOE, an average of 3,549 BOEPD, an raise of 110% contrast to 2013;
- Raised total proved reserves to 26.3 MMBOE, an raise of 99% contrast to 2013;
- Raised oil and natural gas sales to $101.2 million in 2014, an raise of 87% contrast to 2013;
- Adjusted EBITDA of $15.0 million or $0.23 per share (basic) for the fourth quarter of 2014 and $56.8 million or $0.85 per share (basic) for 2014, and;
- Adjusted Net Revenue attributable to ordinary shareholders of $2.0 million or $0.03 per share (basic) for the fourth quarter of 2014 and $16.8 million or $0.25 per share (basic) for the year 2014.
For 2014, Emerald’s total production volumes on a BOE basis raised 110% as contrast to 2013. Production raised due to the addition of 24.19 net productive operated Bakken/Three Forks wells in 2014. During 2014, Emerald realized an $84.01 average price per Bbl of oil (counting settled derivatives) contrast to an $87.16 average price per Bbl of oil during 2013.
As of December 31, 2014, Emerald had total proved reserves of about 26.3 MMBoe, all of which were located in the Williston Basin. Emerald’s proved reserves raised about 99% during 2014 primarily as a result of our successful operated well program. The proved reserves total had a pre-tax PV10% value of $535.1 million.
Emerald is an independent exploration and production operator that is focused on acquiring acreage and developing wells in the Williston Basin of North Dakota and Montana, targeting the Bakken and Three Forks shale oil formations and Pronghorn sand oil formation. Emerald is based in Denver, Colorado.
Alcatel-Lucent (NYSE:ALU)
Bell Labs, the industrial research arm of Alcatel-Lucent (ALU), declared it has launched a discrete consulting division that is committed to apply deep, thoughtful analysis, hands-on experience and sophisticated techo-economic modelling tools to some of the key challenges facing the IT and communications networking industry.
By combining economic acumen and deep technical expertise, particularly in new networking domains, Bell Labs is uniquely positioned to support service provider and vertical customers as they define their future network evolutions and strategies. In the next five years the technology industry will need to re-think how they build, deploy, and operate their network, while making the right technology and market decisions to thrive in the future and avoid being mired in a legacy past.
According to Bell Labs Consulting analysis massive raises in overall network traffic and the types of devices connecting to the network will require new, innovative thinking and bold business plans. Some of these predictions comprise:
- Metro Video traffic will raise 9x by 2020.
- Data center and cloud will raise metro traffic by 6x by 2020.
- Global demand for content on mobile devices will drive 31x traffic growth by 2020; 56% of which will be covered by Wi-Fi.
- SDN can lead to 10X reduction in time to bring new sites onboard in enterprise communications networks.
In addition to these baseline challenges, Bell Labs Consulting will also specialize in work surrounding five key transformational areas of focus:
- The Emergence of the New Enterprise
- The Rise of the Machine
- The Confluence of Networks
- The Move to the Edge Cloud
- The Era of Cognitive Operations
Alcatel-Lucent provides Internet protocol (IP) and cloud networking, and ultra- broadband access worldwide. The corporation’s Core Networking segment offers IP routing, carrier Ethernet, network functions virtualization, and software defined networking applications and infrastructure to meet the challenges of network traffic growth while supporting the delivery of cloud-enabled business, mobile, and residential services for service providers, mobile network operators, cable/multiple system operators, transportation, utilities, and large-scale enterprises.
Molycorp, Inc. (NYSE:MCP)
Formerly on March 16, Molycorp, Inc. (MCP), declared financial and operating results for the fourth quarter and full year 2014.
During the fourth quarter, the Corporation sold 3,149 mt of product at an ASP of $36.91 per kilogram, and generated a gross loss of $44.8 million. This compares to sales volumes of 3,356 mt at an ASP of $36.93 per kilogram and a gross loss of $15.1 million during the third quarter of 2014. The Corporation produced 691 mt and 1,328 mt of rare earth oxides at its Mountain Pass facility during the third and fourth quarters of 2014, respectively. Actual production was lower than predictable as a result of production interruptions while the Corporation continues to optimize operations, and this lower than predictable production has continued through the first two months of 2015.
The Corporation stated negative cash flows from operating activities of $75.8 million during the fourth quarter, and had $211.7 million in cash and cash equivalents as of December 31, 2014.
During the three months ended December 31, 2014, Molycorp’s capital expenditures were $23.3 million on a cash basis.
Molycorp, Inc. produces and sells rare earths and rare metal materials in the United States and internationally. The corporation’s Resources segment extracts rare earth minerals, counting light rare earth concentrates; rare earth oxides (REO), such as lanthanum, cerium, and neodymium-praseodymium; heavy rare earth concentrates, which comprise samarium, europium, gadolinium, terbium, dysprosium, and others; and SorbX and PhosFIX, a line of rare earth-based water treatment products.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
